Since chemical structures of agents in clinical studies in AD, including SSRIs aimed at increasing the SRO level at nerve terminals [18,43], indicate their ability to interact with HSA or/and Aβ, it would be reasonable to complement their trials by tests of the ability of the drug candidates to affect the HSA–Aβ interaction. This evidence concerns the gene ALB and Alzheimer disease.